89bio

89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).

Stock Movers

News

Markets

Movers

Trading Ideas

AKRO

DADA

ETNB

EVER

HAIN

LGIH

LGTY

PTLO

TITN

TKNO

TREE

Dada Nexus, Titan Machinery, AT&amp;T And Other Big Stocks Moving Higher On Monday

Closeup,Of,Wall,St.,Street,Sign,And,Large,New,York

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Earnings

Eurozone

ALLK

ELAB

VERU

Nasdaq Dips 3%; Chicago Fed National Activity Index Rises In December

MDGL

Biotech

Large Cap

Health Care

Media

General

SGMT

VKTX

Madrigal Pharmaceuticals and Sagimet Biosciences shares fall following Eli Lilly&#39;s presentation at the EASL Liver Congress 2024. Phase 2 tirzepatide trial shows promising results for MASH treatment. Further trials needed to confirm efficacy and safety.

What&#39;s Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday?

89bio Inc

Press Releases

89bio to Participate in the 7th Annual Evercore HealthCONx Conference

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

89bio Provides Business Update and Outlook for 2025

Financing

89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

89bio, Inc. Announces Pricing of $250.0 Million Public Offering of Common Stock and Pre-Funded Warrants

89bio Announces Closing of its Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

89bio Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates

89bio to Participate in the Leerink Partners Global Healthcare Conference

Ascentage Pharma Group International - American Depository Shares

Ascentage Pharma Group

Ardelyx

Arcutis Biotherapeutics, Inc. - Common stock

Arcutis Biotherapeutics

CareDx

Celldex Therapeutics, Inc. - Common Stock

Celldex Therapeutics

Dynavax Technologies Corporation - Common Stock

Dynavax Technologies

Dyne Therapeutics

Geron

Galapagos NV - American Depositary Shares

Galapagos

GRAIL

IDEAYA Biosciences

Immunocore Holdings plc - American Depositary Shares

Immunocore Holdings

Iovance Biotherapeutics, Inc. - Common Stock

Iovance Biotherapeutics

Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares

Kiniksa Pharmaceuticals

MiMedx Group

MannKind

Nurix Therapeutics

Novavax

Arcus Biosciences

Syndax Pharmaceuticals, Inc. - Common Stock

Syndax Pharmaceuticals

Spyre Therapeutics

Travere Therapeutics, Inc. - Common Stock

Travere Therapeutics

Vir Biotechnology

Viridian Therapeutics, Inc. - Common Stock

Viridian Therapeutics

Xencor

HC Wainwright & Co.

Cantor Fitzgerald

Raymond James

RBC Capital

Comments

89bio

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga